Back
28
Also listed as
UCBJF
OTC
Day Range
$143.81
$145.91
52-Week Range
$71.16
$168.76
Volume
3,348
50D / 200D Avg
$152.79
/
$129.82
Prev Close
$141.62
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 36.8 | 0.4 |
| P/B | 5.1 | 2.9 |
| ROE % | 14.3 | 3.7 |
| Net Margin % | 20.1 | 3.9 |
| Rev Growth 5Y % | 6.5 | 10.0 |
| D/E | 0.2 | 0.2 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$11.65
$11.29 – $11.93
|
13 B | 1 |
| FY2029 |
$10.16
$9.85 – $10.40
|
12 B | 1 |
| FY2028 |
$8.57
$8.31 – $8.77
|
11 B | 1 |
Key Takeaways
Revenue grew 6.51% annually over 5 years — modest growth
Earnings grew 40.52% over the past year
ROE of 14.33% — decent returns on equity
Net margin of 20.13% shows strong profitability
Debt/Equity of 0.21 — conservative balance sheet
Generating 1.81B in free cash flow
Growth
Revenue Growth (5Y)
6.51%
Revenue (1Y)20.86%
Earnings (1Y)40.52%
FCF Growth (3Y)101.55%
Quality
Return on Equity
14.33%
ROIC6.41%
Net Margin20.13%
Op. Margin15.06%
Safety
Debt / Equity
0.21
Current Ratio1.38
Interest Coverage9.11
Valuation
P/E Ratio
36.79
P/B Ratio5.07
EV/EBITDA49.16
Dividend Yield0.01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 20.86% | Revenue Growth (3Y) | 18.99% |
| Earnings Growth (1Y) | 40.52% | Earnings Growth (3Y) | 108.88% |
| Revenue Growth (5Y) | 6.51% | Earnings Growth (5Y) | 9.06% |
| Profitability | |||
| Revenue (TTM) | 7.44B | Net Income (TTM) | 1.50B |
| ROE | 14.33% | ROA | 8.25% |
| Gross Margin | 71.14% | Operating Margin | 15.06% |
| Net Margin | 20.13% | Free Cash Flow (TTM) | 1.81B |
| ROIC | 6.41% | FCF Growth (3Y) | 101.55% |
| Safety | |||
| Debt / Equity | 0.21 | Current Ratio | 1.38 |
| Interest Coverage | 9.11 | Dividend Yield | 0.01% |
| Valuation | |||
| P/E Ratio | 36.79 | P/B Ratio | 5.07 |
| P/S Ratio | 7.41 | PEG Ratio | 0.76 |
| EV/EBITDA | 49.16 | Dividend Yield | 0.01% |
| Market Cap | 55.06B | Enterprise Value | 55.06B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 7.44B | 6.15B | 5.25B | 5.52B | 5.78B |
| Net Income | 1.50B | 1.07B | 343.00M | 418.00M | 1.06B |
| EPS (Diluted) | 3.86 | 2.74 | 0.88 | 1.08 | 2.73 |
| Gross Profit | 5.29B | 4.40B | 3.55B | 3.84B | 4.34B |
| Operating Income | 1.12B | 1.32B | 604.00M | 585.00M | 1.28B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 18.15B | 17.35B | 15.54B | 15.87B | 14.21B |
| Total Liabilities | 7.29B | 7.32B | 6.56B | 6.80B | 5.82B |
| Shareholders' Equity | 10.86B | 10.03B | 8.98B | 9.06B | 8.39B |
| Total Debt | 2.24B | 3.03B | 3.04B | 2.90B | 2.12B |
| Cash & Equivalents | 2.25B | 1.57B | 861.00M | 899.00M | 1.26B |
| Current Assets | 6.05B | 4.79B | 3.44B | 3.30B | 3.71B |
| Current Liabilities | 4.40B | 3.53B | 2.62B | 3.11B | 2.82B |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#851 of 1024
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026